Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127229162 | 12722916 | 2 | F | 20160829 | 20160908 | 20160926 | PER | US-ASTRAZENECA-2016SE92981 | ASTRAZENECA | 0.00 | F | Y | 0.00000 | 20160926 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127229162 | 12722916 | 1 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | U | 0 | 500 | MG | INJECTION | /month | ||||||
| 127229162 | 12722916 | 2 | PS | ZOLADEX | GOSERELIN ACETATE | 1 | Subcutaneous | 93.6 | MG | 19726 | 3.6 | MG | IMPLANT | /month | |||||
| 127229162 | 12722916 | 3 | SS | ZOLADEX | GOSERELIN ACETATE | 1 | Subcutaneous | 93.6 | MG | 19726 | 3.6 | MG | IMPLANT | /month | |||||
| 127229162 | 12722916 | 4 | SS | ZOLADEX | GOSERELIN ACETATE | 1 | Subcutaneous | 93.6 | MG | 19726 | 3.6 | MG | IMPLANT | /month | |||||
| 127229162 | 12722916 | 5 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | U | 0 | CAPSULE | |||||||||
| 127229162 | 12722916 | 6 | C | BENADRYL | DIPHENHYDRAMINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127229162 | 12722916 | 7 | C | STEROIDS | UNSPECIFIED INGREDIENT | 1 | DAILY | 0 | |||||||||||
| 127229162 | 12722916 | 8 | C | CLARITIN | LORATADINE | 1 | DAILY | 0 | |||||||||||
| 127229162 | 12722916 | 9 | C | ALBUTEROL. | ALBUTEROL | 1 | AS REQUIRED | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127229162 | 12722916 | 1 | Breast cancer female |
| 127229162 | 12722916 | 2 | Breast cancer female |
| 127229162 | 12722916 | 3 | Ovarian disorder |
| 127229162 | 12722916 | 4 | Breast cancer female |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127229162 | 12722916 | Cough | |
| 127229162 | 12722916 | Dyspnoea | |
| 127229162 | 12722916 | Injection site hypoaesthesia | |
| 127229162 | 12722916 | Injection site paraesthesia | |
| 127229162 | 12722916 | Throat tightness | |
| 127229162 | 12722916 | Type IV hypersensitivity reaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127229162 | 12722916 | 1 | 20140703 | 0 | ||
| 127229162 | 12722916 | 2 | 20140703 | 20160823 | 0 | |
| 127229162 | 12722916 | 3 | 20140703 | 20160823 | 0 | |
| 127229162 | 12722916 | 4 | 20140703 | 20160823 | 0 |